DYNE-251
Duchenne Muscular Dystrophy (DMD) amenable to exon 51 skipping
Key Facts
About Dyne Therapeutics
Dyne Therapeutics is executing a focused strategy to become a leader in precision genetic medicine for muscle diseases. The company's core achievement is the development of its FORCE™ platform, an antibody-oligonucleotide conjugate technology designed for muscle-specific delivery, which has now propelled three lead candidates into clinical trials. Its strategy targets large, validated genetic indications—myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD)—with the goal of demonstrating superior efficacy and tolerability. With a cash runway extending into 2026, Dyne is well-positioned to generate critical clinical proof-of-concept data across its pipeline.
View full company profile